When liver cancer is diagnosed at an advanced stage, it is often impossible to remove with surgery. To help patients facing this tough diagnosis, researchers recently tested a novel three-pronged attack. The trial gave 40 patients a combination of chemotherapy delivered directly to the liver, a targeted cancer drug called lenvatinib, and an immunotherapy drug named durvalumab that helps the immune system detect and fight tumors.
The results of this phase 2 trial were highly encouraging. The treatment controlled the disease in 95 percent of the patients and successfully shrank tumors in 75 percent of them. On average, patients lived for nearly 16 months without their cancer growing or spreading. Remarkably, the treatment shrank tumors so much in seven patients (about 17 percent) that surgeons were able to successfully remove their cancer entirely. In three of those surgical cases, doctors found no remaining active cancer cells. Overall, 94 percent of the patients were still alive two years after the treatment began.
Importantly, the therapy proved to be quite safe. About 85 percent of patients experienced only mild to moderate side effects. Doctors did not observe any severe or life-threatening complications, which suggests the treatment is well tolerated by the body.
Breast cancer can sometimes spread to the bones and enter a deep sleep, a process known as cellular dormancy. While this resting state stops the cancer from growing immediately, it allows the cells to hide from treatments and potentially wake up years later. Researchers have now discovered exactly how these rogue cells are lulled to sleep. They found that specific bone-building cells, called osteoblasts, create a safe harbor that holds the cancer cells in a dormant state.
The scientists identified a specific molecular switch responsible for this hibernation. A protein called Notch2 acts as a critical communicator. When breast cancer cells have high levels of Notch2, they start mimicking the behavior of healthy blood stem cells. They activate specific genes, such as CXCR4 and CD34, which drastically slow down their ability to multiply. Interestingly, the researchers proved that a closely related protein, Notch1, plays no role in this process.
When testing these sleeping cells in laboratory mice, the team noticed that the dormant cancer caused much less bone damage. Furthermore, patients whose tumors express high levels of certain dormancy proteins, like CD177, actually tend to live longer, likely because their cancer is resting rather than actively spreading. However, this research is still in its early preclinical stages. The experiments were conducted using laboratory-grown human cell lines and mice with weakened immune systems, meaning more studies are needed before these findings directly impact clinical care.
Multiple myeloma is a persistent type of blood cancer. Recently, a breakthrough treatment called CAR-T cell therapy has given new hope to patients whose cancer has returned or stopped responding to other drugs. This therapy involves engineering a patient's own immune cells to hunt down a specific target on the cancer cells, known as BCMA. While often highly successful at first, the cancer frequently finds a way to hide from the immune system, leading to a relapse.
To understand how these cancer cells escape, researchers used a detailed technique called single-cell RNA sequencing to examine bone marrow samples taken before and after CAR-T treatment. They discovered that the cancer cells actively change their defenses when under attack. Exposure to the engineered immune cells prompts the myeloma cells to pump out large amounts of a protein called CD74, along with a related chemical signal called MIF. This combination acts like a biological shield, allowing the cancer cells to resist dying and continue multiplying.
Armed with this knowledge, the scientists decided to disarm the cancer's newly built defense system. They used an antibody drug called milatuzumab to block the CD74 protein. In laboratory tests and animal models, combining this blocker with standard CAR-T therapy proved highly synergistic. Stripped of their protective protein shield, the residual cancer cells were wiped out more effectively, leading to dramatically smaller tumors and longer survival times in the animal models.
Getting cancer treatment in the morning instead of the afternoon might sound like a simple scheduling choice, but new research suggests it could actually help patients live longer. Researchers looked at patients with stage IV non-small-cell lung cancer, an advanced form of the most common type of lung cancer. They focused on patients receiving a specific type of treatment called immune checkpoint inhibitors. These are drugs that help the body's own immune system recognize and attack cancer cells.
The results showed a noticeable difference based on the clock. Patients who received their infusions before noon lived for a median of 10.3 months, compared to 8.1 months for those treated in the afternoon. To make sure this was not just a coincidence, the scientists also looked at a separate group of 7,951 patients who received traditional chemotherapy instead of immunotherapy. In the chemotherapy group, the time of day made no difference at all. This suggests that the morning benefit is specifically linked to how our immune system naturally fluctuates throughout the day.
While promising, the researchers note that this is an early finding. The study looked back at past medical records from the Veterans Health Administration between 2010 and 2024 rather than setting up a new experiment from scratch. Because it relies on historical data, scientists will need to run new, forward-looking clinical trials to definitively prove that the timing of the treatment is exactly what caused the improved survival.
Prostate cancer screening has long been a subject of debate among medical professionals. Doctors commonly use a blood test called the prostate-specific antigen, or PSA, test to look for early signs of the disease. A massive new review of clinical trials has updated our understanding of how well this test works. The findings suggest that relying on the PSA test alone likely reduces the number of men who die specifically from prostate cancer, and it might even reduce overall death rates compared to not screening at all.
Routine screening naturally leads to a spike in prostate cancer diagnoses, particularly cases that are localized, meaning the cancer has not spread beyond the prostate gland. However, catching these early cases appears to have a protective effect later on. The data shows routine screening could potentially reduce the number of aggressive, metastatic cancers that eventually spread to other parts of the body.
The researchers also looked at a newer screening approach that combines the traditional PSA blood test with a special protein panel, called a kallikrein test, and an MRI scan. So far, early evidence suggests this advanced combination has little to no impact on the number of cancer diagnoses compared to no screening, though it is still too soon to know exactly how it affects long-term survival rates.
Researchers recently set out to answer a crucial global health question: which vaccines save the most lives per dose? To find out, they analyzed vaccination programs for 14 preventable diseases across 117 low-income and middle-income countries. These nations are supported by Gavi, a global health alliance that helps fund and distribute vaccines. By looking at these programs, the researchers calculated an impact ratio for each disease, which simply measures how many deaths are averted for every 1,000 vaccinations given.
Two vaccines stood out clearly from the rest. The vaccine against human papillomavirus, commonly known as HPV, generated the highest impact, preventing just over 11 deaths for every 1,000 vaccinations. The measles vaccine followed closely behind, averting about six deaths per 1,000 doses. For the other vaccines included in the study, the life-saving impact varied significantly based on the specific geographical region and the type of immunization program being run.
However, the researchers are careful to point out some early-stage limitations. Because this is a computer modeling study, it relies on complex mathematical formulas rather than direct real-world counting. The researchers noted that there are built-in uncertainties in the data and the models. Because of these mathematical variables, the estimated impact ratios for many of the vaccines overlap, meaning it is difficult to create a perfect, rigid ranking for every single shot.
A massive study tracking people in Sweden for almost 50 years has pinpointed exactly when our bodies start to lose their physical edge. Researchers discovered that overall fitness, physical strength, and muscle endurance quietly begin to slip around age 35. Rather than maintaining a slow and steady pace, the researchers noted that the rate of this physical decline actually speeds up as the years go by.
However, the study offers a highly encouraging twist for older adults. Even if someone has been inactive for decades, deciding to adopt a physically active lifestyle later in life can still yield major benefits. The researchers found that these late starters actually improved their physical performance by up to 10 percent, proving that the human body remains responsive to exercise well into old age.
While tracking individuals over a five-decade span is a remarkable scientific achievement, there are a few limitations to keep in mind. The research is based entirely on a Swedish cohort, so it is unclear if these exact timelines apply to more diverse global populations. Additionally, the initial data does not specify the exact number of participants or the specific medical tests used to measure their fitness levels.
Mantle cell lymphoma is a challenging type of blood cancer. For years, the standard treatment for younger, relatively fit patients has been a heavy dose of chemotherapy followed by an autologous stem cell transplant. This transplant process involves collecting a patient's own healthy stem cells, delivering high-dose chemotherapy to wipe out the cancer, and then returning the healthy cells to help the body recover. It is an intense procedure that can be incredibly hard on the body.
A recent major clinical trial followed 870 patients across Europe and Israel for over four years to see if adding a targeted daily pill called ibrutinib could improve outcomes. Researchers split the patients into three groups to test different combinations of standard chemotherapy, ibrutinib, and stem cell transplants. They found that adding ibrutinib significantly boosted both how long patients lived overall and how long they lived without their cancer returning or worsening.
The most welcome discovery was that the grueling stem cell transplant may no longer be necessary. The group that received chemotherapy and ibrutinib but skipped the transplant did just as well as the group that received all three. Adding the transplant to the ibrutinib regimen provided no extra survival benefit but significantly increased the risk of severe side effects, like dangerous drops in healthy blood cells. It is worth noting that this study only looked at untreated patients aged 18 to 65, so the findings might not apply to older or less fit individuals.
Have you ever heard a long sentence and wondered how you remembered the subject by the time you reached the verb? Consider a phrase like, "The dog, who chases the cat, jumps over the mud." To understand it, your brain must hold onto the concept of the dog while processing the extra information about the cat. Scientists have long debated whether our brains keep that first word active the entire time or if they store it away and recall it later. Now, researchers using magnetoencephalography, a tool that measures magnetic fields produced by electrical brain activity, have uncovered how we manage this mental juggling.
As participants listened to complex sentences, the neural signal for the original subject completely faded away during the middle section of the sentence. Instead of actively holding the words, the brain uses a mechanism called activity-silent working memory to store the information quietly. When the main verb finally arrives, the brain reactivates the memory of the subject. Interestingly, the brain does not just replay the exact same signal. The neural code is transformed, meaning the brain updates the memory to fit the new grammatical context rather than simply hitting a mental rewind button.
This reactivation happens in a highly coordinated sequence. It begins in the right dorsolateral prefrontal cortex, a brain region that handles general problem solving, before moving into the language-specific frontotemporal regions. The researchers found that the strength of this neural reactivation is directly tied to the structure of the sentence and accurately predicts how well a person will comprehend the information.
When babies are born, their brains are still undergoing massive construction. One crucial building material is myelin, a fatty insulating layer that wraps around nerve fibers to help speed up communication between brain cells. To track this growth in living patients, scientists often rely on a specific magnetic resonance imaging (MRI) measurement called the longitudinal relaxation rate, or R1. Historically, researchers assumed an increasing R1 signal simply meant more myelin was being built. However, new research looking at the human visual cortex, the brain area responsible for processing sight, shows that the story is far more complex.
The researchers discovered that myelination actually happens in two distinct stages. In infants, the growth of this protective insulation is highly restricted to the deep layers of the visual cortex. During this early stage, the rapid increase in the MRI signal is not actually driven by myelin. Instead, it tracks dendritic arborization, which is the process of nerve cells branching out like tiny trees to form new connections.
It is only later, during childhood, that myelin spreads widely across all layers of the visual cortex. By this second phase, the microstructural drivers of the MRI signal shift, and the scans begin to directly match the amount of myelin present in the brain. This shows that the same medical imaging signal can mean two very different things depending on the age of the child.
When it comes to staying protected against COVID-19, a key question is how different booster shots stack up over time. A recent study followed 176 adults who had already received three mRNA vaccine doses to see what happens when they get a fourth shot. Researchers tracked their neutralizing antibodies, which are the specialized proteins the immune system uses to block the virus from infecting cells. The good news is that a fourth dose significantly boosted these protective proteins against newer virus strains, like XBB.1.16, regardless of which vaccine type was used.
However, the vaccines behaved differently in the weeks and months following the shot. Bivalent mRNA vaccines, which are designed to target two different strains of the virus, produced the highest initial defense. Almost a month after vaccination, these shots achieved a 91.7 percent neutralization level against the KP.2 variant. In contrast, the protein-based Novavax vaccine triggered a lower peak of antibodies at first, but those antibodies decayed at a significantly slower rate than those from the mRNA shots.
Despite these different patterns, the playing field eventually leveled out. By the 12-month mark, antibody levels had dropped to a similar baseline across all the vaccine groups. The researchers note that this was a relatively small study. Moving forward, more research is needed to understand whether these different patterns of antibody spikes and slow declines actually translate to better clinical protection against getting sick.
When doctors look inside a patient's stomach using a camera during an endoscopy, they sometimes find areas where the stomach lining has undergone abnormal changes. This condition, known as gastric intestinal metaplasia, is a known warning sign for stomach cancer. Doctors currently use a standard visual grading system to assess this danger, which is already quite effective at diagnosing high-risk cases. However, researchers wanted to see if they could make these predictions even more accurate.
In a recent study of 144 patients, scientists looked closely at the stomach's microvascular patterns, which are the networks of tiny blood vessels in the tissue. They discovered that altered or abnormal blood vessel patterns are a strong, independent predictor that a patient is at a high risk of developing stomach cancer.
By combining the standard grading system with a close look at these blood vessel patterns, the researchers created an upgraded scoring tool. This modified method proved to be highly accurate, successfully identifying 97 percent of the most vulnerable patients. While the researchers note that the study was relatively small and needs to be repeated in larger populations, this upgraded tool shows great promise as a non-invasive way to spot trouble early.
